The primary endpoint of the study was the proportion of patients with plasma HIV-1 RNA ,50 copies/mL at week 48. There were several additional secondary endpoints looking at efficacy and safety of DTG. At week 48, 251 (71%) of 354 patients in the DTG group and 230 (64%) of 361 patients in the RAL group achieved a plasma viral load ,50 copies/mL. The adjusted treatment difference was determined to be 7.4% (95% CI: 0.7–14.2).